ClinicalTrials.gg
Active, not recruitingNCT04818333Updated Jun 13, 2024

A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer

A Phase 1/2 interventional study of SHR-A1811 in Advanced Non-small Cell Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-13.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
157
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing trastuzumab rezetecan in Carcinoma, Non-Small-Cell Lung — 10 open to participants now, 11 under way, 2 of them phase 3. trastuzumab rezetecan · Carcinoma, Non-Small-Cell Lung.

Enrollment
4th of 11
157 · median 60
Started
2021
the only one that year
Phase 1/2
2 of 11
1 open now
Primary completion
2025-06
later than 0 of 10 live
Registered
1st of 11
by date
Lead sponsor
3 of 11
Jiangsu HengRui Medicine Co., Ltd.

Among the 11 studies testing trastuzumab rezetecan in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is the only one that started in 2021, is one of 2 in phase 1/2, reaches primary completion later than 0 of the 10 other live ones, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

10 of the 11 studies testing trastuzumab rezetecan in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About trastuzumab rezetecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing trastuzumab rezetecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is an open-label, two-part study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SHR-A1811 for injection in subjects with advanced non-small cell lung cancer who have HER2 expression , amplification, or mutation

03

Conditions studied

  • Advanced Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. (ECOG) performance status of 0 or 1
  3. advanced non-small cell lung cancer with expression , amplification, or mutation
  4. has previously received platinum-based chemotherapy for advanced or NSCLC, has developed disease progression during or after treatment, or is unable to tolerate platinum-based chemotherapy.
  5. There is at least one according to V1.1 criteria

Exclusion criteria

Exclusion Criteria:

  1. Has unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved to version 5.0 grade ≤ 1.
  2. Has received antibody drug conjugates,
  3. Central nervous system or meningeal metastasis with clinical symptoms
  4. Has active infection requiring systemic treatment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    SHR-A1811

    SHR-A1811 was administered intravenously every 3 weeks (Q3W) until discontinuation treatment

    Drug: SHR-A1811

Interventions

  • Phase 1 Drug: SHR-A1811 There are four pre-defined dose regimens . Subjects will be enrolled with an initial dose Phase 2 Drug: SHR-A1811 Doses will be determined from Phase 1

06

What researchers measure

Primary outcomes

  1. Phase 1:Incidence of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811

    Assess safety and tolerability of SHR-A1811 by way of adverse events (CTCAE v5.0)

    Time frame: From Day 1 to90 days after last dose ,appropriately to 3 years

  2. Phase 1:Severity of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811

    Assess safety and tolerability of SHR-A1811 by way of adverse events (CTCAE v5.0)

    Time frame: From Day 1 to90 days after last dose ,appropriately to 3 years

  3. Phase1: Maximum tolerated dose (MTD)

    Incidence rate and category of dose limiting toxicities (DLTs) during the first 21-day cycle of SHR-A1811 treatment

    Time frame: 12 months

  4. Phase 1: Recommended Phase 2 dose (RP2D)

    RP2D was determined based on the safety, tolerability, PK, immunogenicity data and efficacy information obtained

    Time frame: 12 months

  5. Phase2:ObjectiveResponse Rate (ORR)

    As assessed by RECIST v1.1 , as assessed by independent review committee (IRC)

    Time frame: Subjects were evaluated on tumor imaging every 6 weeks after treatment initiation and every 12 weeks after 54 weeks, until imaging progression, initiation of new antitumor therapy, loss of follow-up, and death,appropriately to 3 years

Secondary outcomes

  1. Phase 1:PK parameter :Tmax of SHRA1811

    Time to maximal concentration (Tmax) of SHR-A1811

    Time frame: appropriately to 3 years

  2. Phase1:PK parameter: Cmax of SHR-A1811

    Maximal concentration (Cmax) of SHR-A1811

    Time frame: appropriately to 3 years

  3. Phase1:PK parameter: AUC0-t of SHR-A1811

    AUC computed from time zero to the time of the last quantifiable concentration (AUC0-t) of SHR-A1811

    Time frame: appropriately to 3 years

  4. Phase1:Immunogenicity of SHR-A1811

    Including anti-drug antibody and/or neutralizing antibody

    Time frame: Immunogenicity sample collection time points include: within 30 min before administration of C1D1, C2D1, C3D1, C4D1, C6D1 and C8D1 starting from cycle 11 only in every 3 cycles ,appropriately to 3 years

  5. Phase2:Progression Free Survival (PFS)

    As assessed by RECIST v1.1 , as assessed by independent review committee (IRC) and investigator

    Time frame: appropriately to 3 years

  6. Phase2:ObjectiveResponse Rate (ORR)

    As assessed by RECIST v1.1 , as assessed by investigator

    Time frame: appropriately to 3 years

  7. Phase2:Duration of response (DOR)

    As assessed by RECIST v1.1 , as assessed by independent review committee (IRC) and investigator

    Time frame: appropriately to 3 years

  8. Phase2:Disease control rate (DCR)

    As assessed by RECIST v1.1 , as assessed by independent review committee (IRC) and investigator

    Time frame: appropriately to 3 years

  9. Phase2:Overall survival (OS)

    Time frame: Approximately 5 years after last subject enrolled

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Jun 2025, 50 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 50 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2021
First posted
Mar 26, 2021
StartActual
Apr 23, 2021
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2025
Last update
Jun 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04818333
Responsible party
Sponsor
First posted
Mar 26, 2021
Start date
Apr 23, 2021
Primary completion
Jun 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Jun 13, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab rezetecan

Start the discussion